Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: A single centre experience

Baroopal, Anil; Sanghvi, Sanjeev; Mathur, Rajani

doi:10.1016/j.ihj.2017.09.134

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary coronary slow flow phenomenon (PCSF) is an angiographic clinical entity, characterized by delayed distal vessel opacification in the absence of significant epicardial coronary stenosis [8].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of P-Selectin In Patients with Slow Coronary Flow.

El-Attar¹,

mohyiAssal²,

El-Amin³

et al. 2018

J Leuk

View full text Add to dashboard Cite

Objective: To evaluate role of P-selectin as a marker of platelets activation in coronary slow flow patients. Patients:A case control study, where seventy two patients underwent cardiac catheterization for suspected coronary artery disease. There were divided into patients group (primary coronary slow flow patients) and control group (normal coronary angiography). Methods:All patients were subjected to history, physical examination and laboratory investigation included CBC serum glucose, lipid profile and immune phenotyping of platelets activation (p selectin CD 62p by flow cytometery). Results:We have two groups: Group1 (patients group): Patients with primary coronary slow flow phenomenon=36 patients. Mean age of cases 49.33 ± 4.99 years with range of (34-55) years. In patients group there was 24 male and 12 female. Group II (control group): Patients with normal coronary angiography=36 patients. Mean age in control group 51.44 ± 3.36 years with range of (43-55) years. Conclusion:The results of the present study revealed that there is very high statistically significant difference in P-selectin level between group 1 (primary coronary slow flow patients) and group 2 (normal coronary angio patients) and there is statistically significant association between P-selectin and TIMI frame count in coronary slow flow.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The patients with coronary slow flow have increased platelet activity compared to control subjects with normal coronary flow [8]. We therefore suggest that sP-selectin could be added as a possible biomarker to identify patients at cardiovascular risk.…”

Section: Introductionmentioning

confidence: 92%

Role of P-Selectin In Patients with Slow Coronary Flow.

El-Attar¹,

mohyiAssal²,

El-Amin³

et al. 2018

J Leuk

View full text Add to dashboard Cite

show abstract

“…P-selectin, expressed on the activated platelets, has been found to have a prominent role in stabilization of platelet aggregates and in size determination of platelet aggregates [7] . The patients with coronary slow flow have increased platelet activity compared to control subjects with normal coronary flow [8] . We therefore suggest that sP-selectin could be added as a possible biomarker to identify patients at cardiovascular risk.…”

Section: Introductionmentioning

confidence: 88%

“…phenomenon (PCSF) is an angiographic clinical entity, characterized by delayed distal vessel opacification in the absence of significant epicardial coronary stenosis. (8) PCSF has direct clinical implications, as it has been linked to clinical manifestations of myocardial ischemia, life-threatening arrhythmias, sudden cardiac death, and recurrent acute coronary syndromes. 9Platelets play important role in the pathogenesis of atherosclerotic complications, contributing to thrombus formation after plaque rupture Following platelet stimulation.…”

Section: Mean X±sdmentioning

confidence: 99%

Role of P-Selectin in Patients With Slow Coronary Flow

El-Attar¹,

mohyiAssal²,

El-Amin³

et al. 2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: sP-selectin is a marker for atherosclerosis and inflammation. It provides prognostic information on cardiovascular events, as reported in the literature. The aim of the present study was to evaluate sP-selectin as a biomarker for cardiovascular mortality in an elderly primary healthcare population, with a focus on possible sex differences Objective: To evaluate role of P-selectin as a marker of platelets activation in coronary slow flow patients. patients: A case control study, where seventy two patients underwent cardiac catheterization for suspected coronary artery disease. There were divided into patients group (primary coronary slow flow patients) and controlgroup(normalcoronaryangiography). Methods:All patients were subjected to history ,physical examination and laboratort investigation included CBC serum glucose,lipid profile and immunophenotyping of platelets activation(p selectin CD 62p by flowcytometery). Results: We have two groups: Group1 (patients group): Patients with primary coronary slow flow phenomenon = 36 patients. Mean age of cases 49.33±4.99 years with range of (34-55) years .In patients group there was 24 male and 12 female. Group II (control group): Patients with normal coronary angiography = 36 patients. Mean age in control group 51.44±3.36 years with range of (43-55) years. Conclusion: The results of the present study revealed that there is very high statistically significant difference in P-selectin level between group 1 (primary coronary slow flow patients) and group 2 (normal coronary angio patients) and there is statistically significant association between P-selectin and TIMI frame count in coronary slow flow.

show abstract

Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: A single centre experience

Cited by 2 publications

References 0 publications

Role of P-Selectin In Patients with Slow Coronary Flow.

Role of P-Selectin In Patients with Slow Coronary Flow.

Role of P-Selectin in Patients With Slow Coronary Flow

Contact Info

Product

Resources

About